Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Drappatz

Showing results (81-90 of 130) with videos related to

Pageof 13
Sort By:
Expert Review of Clinical Immunology|October 15, 2024
Assessment of anti-CD69 antibody therapy alone or in combination with anti-PD-1 in murine GBMMichal Nisnboym, Chaim T Sneiderman, Ambika P Jaswal, et al.
Blood|December 1, 2012
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphomaJames L Rubenstein, Jing Li, Lingjing Chen, et al.
Cancer Research Communications|March 27, 2023
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1-</i> and <i>IDH2</i>-mutant GliomaKristina Fanucci, Mary Jo Pilat, Derek Shyr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Phase II study of protracted daily temozolomide for low-grade gliomas in adultsSantosh Kesari, David Schiff, Jan Drappatz, et al.
Journal of Neuro-Oncology|September 23, 2011
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningiomaDavid A Reardon, Andrew D Norden, Annick Desjardins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLCHideho Okada, Lisa H Butterfield, Ronald L Hamilton, et al.
International Journal of Radiation Oncology, Biology, Physics|February 9, 2010
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastomaJan Drappatz, Andrew D Norden, Eric T Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2013
Phase I study of GRN1005 in recurrent malignant gliomaJan Drappatz, Andrew Brenner, Eric T Wong, et al.
Neuro-Oncology|August 8, 2014
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningiomaThomas J Kaley, Patrick Wen, David Schiff, et al.
Neuro-Oncology|April 12, 2008
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adultsSantosh Kesari, David Schiff, John W Henson, et al.
Pageof 13

Showing results (81-90 of 130) with videos related to

Sort By:
Pageof 13
Expert Review of Clinical Immunology|October 15, 2024
Assessment of anti-CD69 antibody therapy alone or in combination with anti-PD-1 in murine GBMMichal Nisnboym, Chaim T Sneiderman, Ambika P Jaswal, et al.
Blood|December 1, 2012
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphomaJames L Rubenstein, Jing Li, Lingjing Chen, et al.
Cancer Research Communications|March 27, 2023
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1-</i> and <i>IDH2</i>-mutant GliomaKristina Fanucci, Mary Jo Pilat, Derek Shyr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Phase II study of protracted daily temozolomide for low-grade gliomas in adultsSantosh Kesari, David Schiff, Jan Drappatz, et al.
Journal of Neuro-Oncology|September 23, 2011
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningiomaDavid A Reardon, Andrew D Norden, Annick Desjardins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLCHideho Okada, Lisa H Butterfield, Ronald L Hamilton, et al.
International Journal of Radiation Oncology, Biology, Physics|February 9, 2010
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastomaJan Drappatz, Andrew D Norden, Eric T Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2013
Phase I study of GRN1005 in recurrent malignant gliomaJan Drappatz, Andrew Brenner, Eric T Wong, et al.
Neuro-Oncology|August 8, 2014
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningiomaThomas J Kaley, Patrick Wen, David Schiff, et al.
Neuro-Oncology|April 12, 2008
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adultsSantosh Kesari, David Schiff, John W Henson, et al.
Pageof 13